A detailed history of Allworth Financial LP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Allworth Financial LP holds 830 shares of IONS stock, worth $31,274. This represents 0.0% of its overall portfolio holdings.

Number of Shares
830
Previous 809 2.6%
Holding current value
$31,274
Previous $38,000 13.16%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$40.06 - $51.86 $841 - $1,089
21 Added 2.6%
830 $33,000
Q2 2024

Jul 23, 2024

BUY
$36.45 - $47.7 $473 - $620
13 Added 1.63%
809 $38,000
Q1 2024

Apr 25, 2024

BUY
$42.03 - $53.55 $840 - $1,071
20 Added 2.58%
796 $34,000
Q4 2023

Jan 24, 2024

SELL
$43.39 - $51.63 $5,423 - $6,453
-125 Reduced 13.87%
776 $39,000
Q3 2023

Oct 31, 2023

BUY
$38.5 - $47.13 $1,617 - $1,979
42 Added 4.89%
901 $40,000
Q2 2023

Jul 18, 2023

BUY
$34.73 - $43.33 $2,292 - $2,859
66 Added 8.32%
859 $35,000
Q1 2023

Apr 18, 2023

SELL
$33.58 - $41.2 $134 - $164
-4 Reduced 0.5%
793 $28,000
Q3 2022

Oct 18, 2022

BUY
$36.54 - $48.66 $2,119 - $2,822
58 Added 7.85%
797 $35,000
Q1 2022

Apr 22, 2022

BUY
$29.88 - $37.04 $239 - $296
8 Added 1.09%
739 $27,000
Q4 2021

Jan 21, 2022

BUY
$25.61 - $35.1 $18,285 - $25,061
714 Added 4200.0%
731 $22,000
Q2 2020

Jul 24, 2020

SELL
$46.85 - $61.05 $327 - $427
-7 Reduced 29.17%
17 $1,000
Q4 2019

Jan 16, 2020

BUY
$53.85 - $65.27 $915 - $1,109
17 Added 242.86%
24 $1,000
Q1 2019

May 07, 2019

BUY
$52.92 - $81.17 $370 - $568
7 New
7 $1,000
Q2 2018

Aug 08, 2018

SELL
$40.53 - $50.7 $1,175 - $1,470
-29 Closed
0 $0
Q1 2018

May 02, 2018

BUY
$44.08 - $55.05 $1,278 - $1,596
29 New
29 $1,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.